Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future
about
Potential of nanoparticles for allergen-specific immunotherapy - use of silica nanoparticles as vaccination platform.Recombinant production of influenza hemagglutinin and HIV-1 GP120 antigenic peptides using a cleavable self-aggregating tag.In silico Identification of Potential Peptides or Allergen Shot Candidates Against Aspergillus fumigatusLactobacillus buchneri S-layer as carrier for an Ara h 2-derived peptide for peanut allergen-specific immunotherapy.NMR resonance assignments of a hypoallergenic isoform of the major birch pollen allergen Bet v 1.Epitope Mapping of Rhi o 1 and Generation of a Hypoallergenic Variant: A CANDIDATE MOLECULE FOR FUNGAL ALLERGY VACCINES.Immunomodulating peptides for food allergy prevention and treatment.Novel approaches and perspectives in allergen immunotherapy.Adjuvants for allergy immunotherapeutics.Molecular aspects of allergens in atopic dermatitisMechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells.Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis.Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.Clustering of conformational IgE epitopes on the major dog allergen Can f 1.Patching it together: epicutaneous vaccination with heat-labile Escherichia coli toxin against birch pollen allergy.Therapeutic vaccines for allergic disease.Similar localization of conformational IgE epitopes on the house dust mite allergens Der p 5 and Der p 21 despite limited IgE-cross-reactivity.Next generation immunotherapy for tree pollen allergies.Hydrolysed ovalbumin offers more effective preventive and therapeutic protection against egg allergy than the intact protein.Characterization of maize chitinase-A, a tough allergenic molecule.Preparation and Analysis of Peanut Flour Used in Oral Immunotherapy Clinical Trials.Pru p 3-Epitope-based sublingual immunotherapy in a murine model for the treatment of peach allergy.A modified, hypoallergenic variant of the Ricinus communis Ric c1 protein retains biological activity.Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches.Cari p 1, a Novel Polygalacturonase Allergen From Papaya Acting as Respiratory and Food Sensitizer.Heterogeneity of Ara h Component-Specific CD4 T Cell Responses in Peanut-Allergic Subjects.Microbial Delivery Vehicles for Allergens and Allergen-Derived Peptides in Immunotherapy of Allergic Diseases.
P2860
Q36056484-F0105A09-232B-4BA9-AB6E-D7205BB64A39Q37390576-C2C0B844-CF15-4A4B-9B3C-AF60A9F13621Q37424930-C3459659-88E2-4AE2-BD33-A0360F80E40CQ37744450-5CE74A67-547F-405C-A648-84ACDB2C2E5FQ38624601-E7321412-6FD5-4F60-BF18-EC2AFD89EA95Q38760754-29012BBA-2E17-4EE2-9BA0-408F79AB0229Q39094939-B50AD589-490A-438F-84D8-19BBCF37EB61Q39103046-C60D57BD-E44D-4F23-B27E-5504512F1124Q39151158-A9A66B15-D8A2-49C4-90E7-5FD66B04C709Q39378515-2702A927-052F-4800-9A5E-5AAE22ADC9AAQ39402881-2DA467FA-49BE-4C90-B19D-AFBC5A660E7AQ40087434-41089918-8F03-405E-A595-C6011B3BD790Q40135722-873CB76F-2B2C-493C-8753-69FD18B4F014Q41769755-894ACE76-1B73-4BDE-B9CE-DD1C8A36F5B0Q42252694-484D75B3-E38C-44FA-BDDD-A4434FFABD66Q46358611-5D3D709A-1A37-4938-9276-0F0B0D6AA8A6Q47100584-C4BA0A23-B163-461C-9049-F0D347B3C96BQ47214140-6DDE4EDE-DD25-4690-9B2F-9104E21BD61FQ47884083-2BBB99F9-DD57-4CC7-85A2-AF86B0CCD0A2Q48004655-51093914-0AA9-4D97-92EE-27EF9172149EQ48093165-9D30DA2A-CB77-4483-9699-ED560C20B117Q49956390-2DE5E493-E348-48BC-AC5F-1CA4FB17B173Q50957303-82F77270-2283-468F-B428-E3864CF801E3Q52695058-4F6BDAE8-A424-4A0D-B21D-4749B943DD1AQ52766596-9E1C647C-9E60-4A0C-A755-B2F9FB1B1578Q55277398-61FA5D69-2F5F-420C-ADD9-2C0B8CF63574Q55436442-6DBDD1EC-DCDC-43EA-BBEA-F3EF4D9D9D65Q55450722-C22CA8F5-85AF-4315-8D96-C2530E0F7F34Q55516309-71DEBDE9-4B64-4829-8E82-1A394E3870C5Q55693712-552CE7B2-FD95-4A42-B285-144D9E77875C
P2860
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Vaccine development for allerg ...... nisms of action for the future
@ast
Vaccine development for allerg ...... nisms of action for the future
@en
Vaccine development for allerg ...... nisms of action for the future
@nl
type
label
Vaccine development for allerg ...... nisms of action for the future
@ast
Vaccine development for allerg ...... nisms of action for the future
@en
Vaccine development for allerg ...... nisms of action for the future
@nl
prefLabel
Vaccine development for allerg ...... nisms of action for the future
@ast
Vaccine development for allerg ...... nisms of action for the future
@en
Vaccine development for allerg ...... nisms of action for the future
@nl
P2093
P2860
P921
P1476
Vaccine development for allerg ...... nisms of action for the future
@en
P2093
Margit Focke-Tejkl
Raffaela Campana
Verena Niederberger
P2860
P356
10.1016/J.JACI.2015.12.1299
P407
P577
2016-02-01T00:00:00Z